CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-06 | Metzger Michael A Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −5,959 | $27.64 | $165K | 0 |
| 2023-02-06 | Morrison Briggs President, Head of R&D | Option exercise | +52,854 | $6.38 | $337K | 70,690 |
| 2023-02-06 | Morrison Briggs President, Head of R&D | Sale | −52,854 | $26.83 | $1.4M | 17,836 |
| 2023-02-06 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −52,854 | 0 | ||
| 2023-02-02 | Metzger Michael A Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +410,000 | $28.55 | $11.7M | 410,000 |
| 2023-02-02 | Morrison Briggs President, Head of R&D | Grant or award · Stock Options (Right to buy) | +32,000 | $28.55 | $914K | 32,000 |
| 2023-02-02 | Madigan Catherine Chief Medical Officer | Grant or award · Stock Options (Right to buy) | +110,000 | $28.55 | $3.1M | 110,000 |
| 2023-02-02 | Goldan Keith A. Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +110,000 | $28.55 | $3.1M | 110,000 |
| 2023-02-02 | Ordentlich Peter Chief Scientific Officer | Grant or award · Stock Options (Right to buy) | +90,000 | $28.55 | $2.6M | 90,000 |
| 2023-02-02 | Nolte Alexander Chief Accounting Officer | Grant or award · Stock Options (Right to buy) | +17,000 | $28.55 | $485K | 17,000 |
| 2023-02-02 | Podlesak Dennis Director | Grant or award | +32,000 | 107,763 | ||
| 2023-02-02 | Huber Martin H. Jr. Director | Grant or award | +16,000 | 32,000 | ||
| 2023-02-02 | Meury William Director | Grant or award | +16,000 | 48,000 | ||
| 2023-02-02 | Legault Pierre Director | Grant or award | +16,000 | 48,000 | ||
| 2023-02-02 | Katkin Keith Director | Grant or award | +16,000 | 48,000 | ||
| 2023-02-02 | Jarrett Jennifer Director | Grant or award | +16,000 | 48,000 | ||
| 2023-02-01 | Ordentlich Peter Chief Scientific Officer | Sale | −69 | $28.43 | $2K | 0 |
| 2023-01-31 | Ordentlich Peter Chief Scientific Officer | Other acquisition | +69 | $17.32 | $1K | 69 |
| 2023-01-13 | Legault Pierre Director | Option exercise | +10,000 | $13.58 | $136K | 42,000 |
| 2023-01-13 | Legault Pierre Director | Sale | −10,000 | $27.00 | $270K | 32,000 |
Page 8 of 15 · 290 trades